AR106049A1 - Formulaciones de liberación controlada - Google Patents

Formulaciones de liberación controlada

Info

Publication number
AR106049A1
AR106049A1 ARP160102828A ARP160102828A AR106049A1 AR 106049 A1 AR106049 A1 AR 106049A1 AR P160102828 A ARP160102828 A AR P160102828A AR P160102828 A ARP160102828 A AR P160102828A AR 106049 A1 AR106049 A1 AR 106049A1
Authority
AR
Argentina
Prior art keywords
vomiting
nausea
compositions
preformulation
controlled release
Prior art date
Application number
ARP160102828A
Other languages
English (en)
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of AR106049A1 publication Critical patent/AR106049A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente se refiere a una preformulación inyectable que comprende una mezcla de baja viscosidad de: a) al menos un lípido de diacilo neutro y/o al menos un tocoferol; b) al menos un fosfolípido; c) al menos un solvente orgánico que contiene oxígeno; d) al menos un antagonista de 5HT₃; en donde la preformulación forma, o es capaz de formar, al menos una estructura de fase cristalina líquida tras el contacto con un fluido acuoso. Tales composiciones pueden comprender, además, solventes polares y/o agentes activos adicionales, tales como agonistas y/o antagonistas de opioides. Se proporcionan métodos de tratamiento, en particular para el tratamiento de náuseas y vómitos tales como náuseas y vómitos posoperatorios y/o náuseas y vómitos inducidos por la terapia, así como los correspondientes usos de las composiciones. También se proporcionan dispositivos de administración que comprenden las formulaciones y kits que comprenden los dispositivos.
ARP160102828A 2015-09-18 2016-09-16 Formulaciones de liberación controlada AR106049A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1516554.1A GB201516554D0 (en) 2015-09-18 2015-09-18 Controlled-release formulations

Publications (1)

Publication Number Publication Date
AR106049A1 true AR106049A1 (es) 2017-12-06

Family

ID=54544453

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102828A AR106049A1 (es) 2015-09-18 2016-09-16 Formulaciones de liberación controlada

Country Status (13)

Country Link
US (1) US20180256496A1 (es)
EP (1) EP3349800A1 (es)
JP (1) JP2018528964A (es)
KR (1) KR20180085716A (es)
CN (1) CN108601843A (es)
AR (1) AR106049A1 (es)
AU (1) AU2016323732A1 (es)
CA (1) CA2998966A1 (es)
GB (1) GB201516554D0 (es)
HK (1) HK1258718A1 (es)
MX (1) MX2018003333A (es)
TW (1) TW201717946A (es)
WO (1) WO2017046384A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102098980B1 (ko) 2012-07-26 2020-04-08 카무러스 에이비 오피오이드 제형
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CA3116004A1 (en) * 2018-10-11 2020-04-16 Indivior Uk Limited Buprenorphine to treat respiratory depression
AU2020342591A1 (en) 2019-09-02 2022-03-03 Camurus Ab Formulations and treatment methods
WO2021064580A1 (en) * 2019-10-01 2021-04-08 Shilpa Medicare Limited Controlled release injectable ondansetron formulations
CN113081954A (zh) * 2021-05-25 2021-07-09 南昌大学第二附属医院 一种凝胶载药贴剂药物输送系统
CN115702894A (zh) * 2021-08-11 2023-02-17 朱信红 一种用于止吐的缓释组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
CA2594718C (en) * 2005-01-14 2012-01-24 Camurus Ab Gnrh analogue formulations
US9226918B2 (en) * 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
SG11201402673YA (en) * 2011-12-05 2014-06-27 Camurus Ab Robust controlled-release formulations
KR102098980B1 (ko) * 2012-07-26 2020-04-08 카무러스 에이비 오피오이드 제형
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US20140323517A1 (en) * 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system

Also Published As

Publication number Publication date
MX2018003333A (es) 2018-08-15
KR20180085716A (ko) 2018-07-27
CN108601843A (zh) 2018-09-28
TW201717946A (zh) 2017-06-01
EP3349800A1 (en) 2018-07-25
GB201516554D0 (en) 2015-11-04
JP2018528964A (ja) 2018-10-04
HK1258718A1 (zh) 2019-11-15
US20180256496A1 (en) 2018-09-13
WO2017046384A1 (en) 2017-03-23
AU2016323732A1 (en) 2018-04-12
CA2998966A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
AR106049A1 (es) Formulaciones de liberación controlada
ECSP13013107A (es) Formulaciones peptídicas de liberación controlada
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CL2019002032A1 (es) Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018).
AR089554A1 (es) Formas cristalinas de un inhibidor de la dipeptidil peptidasa-iv
ECSP19024046A (es) Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
PE20190973A1 (es) Compuestos de tetrahidropirazolopirimidina
CL2016000313A1 (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
BR112016028961A8 (pt) fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit
BR112017013471A2 (pt) Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
BR112014003566B8 (pt) composição líquida, processo para a preparação da composição líquida, e, uso de um líquido iônico
UY35293A (es) Isotiazoles sustituidos con amino
CL2017001024A1 (es) Formulación de buprenorfina inyectable
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
PE20160004A1 (es) Metodo y aparato para tratamiento magnetico/electrostatico/electromagnetico de fluidos comprendiendo tres fases: la fase de tratamiento, la fase de mezcla y la fase de uso las cuales estan espacial y temporalmente desacopladas
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
AR099097A1 (es) SUSPOEMULSIÓN ACUOSA QUE CONTIENE l-CIALOTRINA Y MÉTODOS PARA PRODUCIR Y USAR LA MISMA
PE20150928A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
ECSP15003613A (es) Formulación transdérmica que contiene inhibidores de cox
CL2015000197A1 (es) Formulaciones de opioides
AR105503A1 (es) Concentrado que contiene alprostadil
PE20171305A1 (es) Formulaciones inyectables de paracetamol
AR100815A1 (es) Formulaciones parasiticidas transdérmicas, método, uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure